- Home
- VIVK vs BIVI Comparison
VIVK vs BIVI Comparison
Compare VIVK & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVK
- BIVI
- Stock Information
- Founded
- VIVK 2006
- BIVI 2013
- Country
- VIVK United States
- BIVI United States
- Employees
- VIVK N/A
- BIVI N/A
- Industry
- VIVK Oilfield Services/Equipment
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- VIVK Energy
- BIVI Health Care
- Exchange
- VIVK Nasdaq
- BIVI Nasdaq
- Market Cap
- VIVK 50.4M
- BIVI 49.8M
- IPO Year
- VIVK N/A
- BIVI N/A
- Fundamental
- Price
- VIVK $1.09
- BIVI $1.93
- Analyst Decision
- VIVK
- BIVI Strong Buy
- Analyst Count
- VIVK 0
- BIVI 1
- Target Price
- VIVK N/A
- BIVI $30.00
- AVG Volume (30 Days)
- VIVK 56.2K
- BIVI 1.0M
- Earning Date
- VIVK 11-19-2024
- BIVI 02-11-2025
- Dividend Yield
- VIVK N/A
- BIVI N/A
- EPS Growth
- VIVK N/A
- BIVI N/A
- EPS
- VIVK N/A
- BIVI N/A
- Revenue
- VIVK $61,991,772.00
- BIVI N/A
- Revenue This Year
- VIVK N/A
- BIVI N/A
- Revenue Next Year
- VIVK N/A
- BIVI N/A
- P/E Ratio
- VIVK N/A
- BIVI N/A
- Revenue Growth
- VIVK 0.33
- BIVI N/A
- 52 Week Low
- VIVK $0.67
- BIVI $1.04
- 52 Week High
- VIVK $3.45
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- VIVK 44.43
- BIVI 38.67
- Support Level
- VIVK $1.03
- BIVI $1.86
- Resistance Level
- VIVK $1.25
- BIVI $2.29
- Average True Range (ATR)
- VIVK 0.17
- BIVI 0.19
- MACD
- VIVK 0.01
- BIVI -0.01
- Stochastic Oscillator
- VIVK 33.33
- BIVI 9.78
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is primarily focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.